Compare Summit Therapeutics Inc (SMMT) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Summit Therapeutics Inc trades at $17.58 (market cap $13.98B), while Vanguard Total Stock Market Index Fund ETF trades at $376.51. The key difference: Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | VTI | |
|---|---|---|
Market Cap | $13.98B | — |
Sector | Health | — |
52-Week High | $26.38 | $384.30 |
52-Week Low | $12.43 | $311.68 |
Enterprise Value | $13.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
VTI trades at $377.6, down 0.56% on the day, with a neutral technical signal. The ETF offers broad U.S. stock market exposure across 3,515 companies. Recent news highlights its role in diversified portfolios, with institutional buying noted. Moving averages show a bullish trend, while oscillators are neutral, indicating mixed short-term momentum.
Long-term outlook remains positive given historical market returns, but concentration risk exists with top holdings. Key risks include market volatility and economic downturns. Analyst sentiment is generally favorable for buy-and-hold strategies, emphasizing low costs and diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
